A phase II study of etoposide, doxorubicin, and carboplatin in the treatment of advanced gastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 1, 2002, Pages 71-75

  Wang, Xiaobo ^a   Pang, Liangxi ^a   Feng, Jifeng ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Advanced gastric cancer; Carboplatin; Chemotherapy; Doxorubicin; Etoposide

Indexed keywords

CARBOPLATIN; DOXORUBICIN; ETOPOSIDE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MALE; PHASE 2 CLINICAL TRIAL; STOMACH CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; FEMALE; GASTRECTOMY; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0036159646     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200202000-00015     Document Type: Article

References (38)

1. Cancer statistics, 1997
2. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer
3. The nature history and results of surgical therapy for carcinoma of the stomach. An analysis of 250 cases
4. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer
5. Drug combinations in the treatment of gastric adenocarcinoma: A randomized Southwest oncology group study
6. An EORTC gastrointestinal group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and Adriamycin in advanced gastric cancer
7. 5-FU infusion with mitomycin c versus 5-FU infusion with methyl-CCNU in treatment of advanced upper gastrointestinal cancer
8. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277)
9. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: Implications for future studies
10. Therapy of upper gastrointestinal tract cancers
11. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas
12. New developments in the treatment of gastric carcinoma
13. Epirubicin, cisplatin and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer: An Italy Group for the study of digestive tract cancer (GISCAP) report
14. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: Results of a phase II trial
15. Treatment of gastric adenocarcinoma with the combination of etoposide, Adriamycin and cisplatin (EAP): Comparison between two schedules
16. Nonparametric estimation from incomplete observations
17. Chemotherapy of gastric cancer: A review
18. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer
19. A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer
20. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of advanced gastric cancer. A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group
21. FAMTX (fluorouracil, methotrexate, Adriamycin) is as effective and less toxic than EAP (etoposide, Adriamycin, cisplatin): A random assignment trial in gastric cancer
22. A randomized trial comparing ECF with FAMTX in advanced oesophago-gastric cancer
23. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer (gastric cancer): A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (Arbeitsgemeinschaft Internistische Onkologie)
24. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer
25. EAP in advanced gastric cancer
26. Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer
27. Combination of etoposide, Adriamycin, and cisplatin (EAP) in gastric cancer: Association with severe toxicity
28. FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer
29. Combination of etoposide, Adriamycin, and cisplatin (EAP) in gastric cancer: Association with severe toxicity
30. Phase II trial of VP-16, adriamycin, and cisplatinum in patients with advanced gastric cancer
31. Combination chemotherapy with etoposide, Adriamycin and cisplatin (EAP) for advanced gastric cancer
32. Etoposide, doxorubicin and cisplatin for advanced gastric adenocarcinoma: Results of a phase II trial
33. Antitumor activity of(2″R)-4′-O-tetrahydropyranyl Adriamycin on human gastric cancer cell lines in vitro and in vivo
34. Carboplatin: Current status and future prospects
35. A phase II study of carboplatin in advanced or metastatic stomach cancer
36. Carboplatin and etoposide in patients with advanced gastric cancer
37. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer
38. Phase II clinical study of carboplatin: An observation of 529 cases